Abstract 245: Cost Effectiveness and Safety of Abbreviated Eptifibatide Infusion in Veterans Undergoing Percutaneous Coronary Intervention [Session Title: Poster Session II]
Conclusion: In this real world cohort of patients undergoing PCI, an abbreviated 2 hour eptifibatide infusion after PCI was safe and had a cost savings of greater than 50% per patient, when compared with a standard 18 hour infusion. This approach is more cost-effective and should be considered in patients undergoing PCI who are not pretreated with dual antiplatelet therapy. (Source: Circulation: Cardiovascular Quality and Outcomes)
Source: Circulation: Cardiovascular Quality and Outcomes - April 29, 2015 Category: Cardiology Authors: Ghadban, R., Shah, A., Ampadu, J., Linneman, T., Thomas, J.-A., Forsberg, M., Stolker, J., Klein, A. Tags: Session Title: Poster Session II Source Type: research
Loading doses of aspirin and clopidogrel prior to Enterprise stent-assisted repair of intracranial aneurysm-a pilot study (P3.117)
Conclusions: Loading dose of antiplatelet in Enterprise stent-assisted repair of intracranial aneurysm is not only safe and feasible but associated with good clinical outcome. Therefore, loading doses antiplatelets is an alternative option for patients who are candidates for stent-assisted repair of intracranial aneurysm.Disclosure: Dr. Lodi has nothing to disclose. Dr. Reddy has nothing to disclose. Dr. Devasenapathy has nothing to disclose. Dr. Shehadeh has nothing to disclose. Dr. Hourini has nothing to disclose. Dr. Chou has nothing to disclose. (Source: Neurology)
Source: Neurology - April 8, 2015 Category: Neurology Authors: Lodi, Y., Reddy, V., Devasenapathy, A., Shehadeh, K., Hourini, A., Chou, C.-A. Tags: Cerebrovascular Disease and Interventional Neurology: Subarachnoid Hemorrhage and Miscellany Source Type: research
Using Zero-Balance Ultrafiltration With Dialysate as a Replacement Solution for Toxin and Eptifibatide Removal on a Dialysis-Dependent Patient During Cardiopulmonary Bypass
C ARDIAC DISEASE is very prevalent in patients with end-stage renal disease (ESRD) dependent on hemodialysis (HD).1 While HD-dependent patients commonly are referred for cardiac surgery, their multiple comorbidities, including diabetes, peripheral vascular disease, anemia and cachexia, and others, make perioperative management challenging.2,3 It has been shown that perioperative management of fluid balance, electrolytes, metabolic acidosis, and azotemia plays an important role in operative morbidity and mortality in these patients. (Source: Journal of Cardiothoracic and Vascular Anesthesia)
Source: Journal of Cardiothoracic and Vascular Anesthesia - April 6, 2015 Category: Anesthesiology Authors: Michele Heath, Atilio Barbeito, Ian Welsby, Cory Maxwell, Alexander Iribane, Karthik Raghunathan Tags: Case Report Source Type: research
Eptifibatide in Post Infarction Angina Patients who Refused Intervention: Ajmer post‐Myocardial infarction angina Eptifibatide Research (AJMER) study: A Pilot Study
ConclusionIn patients with PIA who refused intervention, eptifibatide infusion resulted in earlier relief of angina albeit at cost of increased non–life‐threatening bleedings. Further this effect was achieved in significantly higher number of patients receiving eptifibatide infusion when compared to patients not receiving it. Primary composite end points, although did not differ in two groups, but being a pilot study this needs to be confirmed by larger study of adequate sample size.This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - April 1, 2015 Category: Cardiology Authors: R.K. Gokhroo, Kamal Kishor, Bhanwar Ranwa, Devendra Singh Bisht, Sajal Gupta, A Avinash Tags: Original Research Article Source Type: research
Platelet Activation and Aggregation Promote Lung Inflammation and Influenza Virus Pathogenesis.
Conclusions: The intricate relationship between hemostasis and inflammation has major consequences in influenza virus pathogenesis, and anti-platelet drugs might be explored to develop new anti-inflammatory treatment against influenza virus infections. Key words: Lung injury, novel drugs, Flu pathogenesis, pneumonia, platelets.
PMID: 25664391 [PubMed - as supplied by publisher] (Source: American Journal of Respiratory and Critical Care Medicine)
Source: American Journal of Respiratory and Critical Care Medicine - February 9, 2015 Category: Respiratory Medicine Authors: Lê VB, Schneider JG, Boergeling Y, Berri F, Ducatez M, Guerin JL, Adrian I, Errazuriz-Cerda E, Frasquilho S, Antunes L, Lina B, Bordet JC, Jandrot-Perrus M, Ludwig S, Riteau B Tags: Am J Respir Crit Care Med Source Type: research
Eptifibatide in Coronary Intervention: Past Time for the Next Chapter [Editorials]
(Source: Circulation: Cardiovascular Interventions)
Source: Circulation: Cardiovascular Interventions - February 5, 2015 Category: Cardiology Authors: Sherwood, M. W., Tcheng, J. E. Tags: Cardiovascular Pharmacology, Platelet function inhibitors, Catheter-based coronary interventions: stents, Platelets Editorials Source Type: research
Comparative Effectiveness and Safety of a Catheterization Laboratory-Only Eptifibatide Dosing Strategy in Patients Undergoing Percutaneous Coronary Intervention [Coronary Interventions]
Conclusions—
A catheterization laboratory–only eptifibatide regimen is commonly used in clinical practice and is associated with a significant reduction in bleeding complications in patients undergoing contemporary percutaneous coronary intervention. (Source: Circulation: Cardiovascular Interventions)
Source: Circulation: Cardiovascular Interventions - February 5, 2015 Category: Cardiology Authors: Gurm, H. S., Hosman, C., Bates, E. R., Share, D., Hansen, B. B., for the Blue Cross Blue Shield of Michigan Cardiovascular Consortium Tags: Cardiovascular Pharmacology Coronary Interventions Source Type: research
Recombinant Tissue-Type Plasminogen Activator Plus Eptifibatide Versus Recombinant Tissue-Type Plasminogen Activator Alone in Acute Ischemic Stroke: Propensity Score-Matched Post Hoc Analysis [Clinical Sciences]
Conclusion—
r-tPA plus eptifibatide showed a favorable direction of effect that was consistent across multiple approaches for AIS outcome evaluation. A phase III trial to establish the efficacy of r-tPA plus eptifibatide for improving AIS outcomes is warranted. (Source: Stroke)
Source: Stroke - January 26, 2015 Category: Neurology Authors: Adeoye, O., Sucharew, H., Khoury, J., Tomsick, T., Khatri, P., Palesch, Y., Schmit, P. A., Pancioli, A. M., Broderick, J. P., for The CLEAR-ER, IMS III, and ALIAS Part 2 Investigators Tags: Acute Cerebral Infarction, Emergency treatment of Stroke, Thrombolysis Clinical Sciences Source Type: research
Thrombocytopenia in Acute Coronary Syndromes: Etiologies and Proposed Management
We present a case of profound thrombocytopenia due to administration of a GPRA, eptifibatide, following percutaneous coronary intervention (PCI) for an inferior ST elevation myocardial infarction (STEMI). We review the major causes and suggest an approach for diagnosis and management of thrombocytopenia in ACS (Source: Canadian Journal of Cardiology)
Source: Canadian Journal of Cardiology - January 17, 2015 Category: Cardiology Source Type: research
Rescue Treatment of Thromboembolic Complications during Endovascular Treatment of Cerebral Aneurysms: A Meta-Analysis [FELLOWS' JOURNAL CLUB]
CONCLUSIONS:
Rescue therapy with thrombolytic agents resulted in significantly more morbidity than rescue therapy with glycoprotein IIb/IIIa inhibitors. Tirofiban/eptifibatide resulted in significantly higher recanalization rates compared with abciximab. (Source: American Journal of Neuroradiology)
Source: American Journal of Neuroradiology - January 13, 2015 Category: Radiology Authors: Brinjikji, W., Morales-Valero, S. F., Murad, M. H., Cloft, H. J., Kallmes, D. F. Tags: FELLOWS ' JOURNAL CLUB Source Type: research
Effect of a Shortened-Duration Infusion (75 mg) as Adjunctive Therapy for Percutaneous Coronary Intervention on Inhospital Cardiovascular Outcomes and Bleeding
A retrospective cohort analysis was conducted on patients who underwent percutaneous coronary intervention (PCI) before and after a practice change which reduced the infusion duration of eptifibatide from 18 hours to the time required for completion of a single vial of 75 mg initiated during PCI. Primary end points were inhospital cardiovascular events, target vessel revascularization, and major or minor bleeding. The secondary end point was drug cost. A total of 1,647 patients received the standard-duration infusion (18 hours), and 1,237 received the short-duration infusion. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - January 5, 2015 Category: Cardiology Authors: Scott D. Nei, Jeffrey J. Armon, Ross A. Dierkhising, Malcolm R. Bell, Verghese Mathew, Gregory W. Barsness, Narith N. Ou Tags: Coronary Artery Disease Source Type: research
Effect of a Shortened Duration Eptifibatide Infusion (75 mg) as Adjunctive Therapy for Percutaneous Coronary Intervention on In-Hospital Cardiovascular Outcomes and Bleeding
A retrospective cohort analysis was conducted on patients undergoing percutaneous coronary intervention (PCI) before and after a practice change which reduced the infusion duration of eptifibatide from 18 hours to the time required for completion of a single vial of 75 mg initiated during PCI. Primary endpoints were in-hospital cardiovascular events, target vessel revascularization, and major or minor bleeding. The secondary endpoint was drug cost. A total of 1,647 patients received the standard duration infusion (18 hours), and 1,237 received the short duration infusion. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - January 5, 2015 Category: Cardiology Authors: Scott D. Nei, Jeffrey J. Armon, Ross A. Dierkhising, Malcolm R. Bell, Verghese Mathew, Gregory W. Barsness, Narith N. Ou Tags: CORONARY ARTER DISEASE Source Type: research
Prophylaxis of Experimental Endocarditis With Antiplatelet and Antithrombin Agents: A Role for Long-term Prevention of Infective Endocarditis in Humans?
Conclusions. Antiplatelet and direct antithrombin agents may be useful in the prophylaxis of IE in humans. In particular, the potential dual benefit of dabigatran etexilate might be reconsidered for patients with prosthetic valves, who require life-long anticoagulation and in whom S. aureus IE is associated with high mortality. (Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - December 12, 2014 Category: Infectious Diseases Authors: Veloso, T. R., Que, Y.-A., Chaouch, A., Giddey, M., Vouillamoz, J., Rousson, V., Moreillon, P., Entenza, J. M. Tags: BACTERIA Source Type: research
Local Intracoronary Eptifibatide versus Mechanical Aspiration in Patients with Acute ST-Elevation Myocardial Infarction.
Conclusion. Local intracoronary eptifibatide by perfusion catheter reduces thrombus burden with better results in microvascular perfusion assessed by cTFC and MBG compared to aspiration device or conventional PCI.
PMID: 24987529 [PubMed] (Source: International Journal of Vascular Medicine)
Source: International Journal of Vascular Medicine - December 1, 2014 Category: Cardiology Tags: Int J Vasc Med Source Type: research
Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab.
Authors: Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C
Abstract
Tirofiban is a nonpeptide tyrosine derivative that together with eptifibatide (both small molecules) and abciximam belongs to the group of glycoprotein IIb/IIIa inhibitors. Though similar to abciximab in that it has a high affinity for the GP IIbIIIa inhibitor receptor, tirofiban dissociates from it much faster tan abciximab, what makes its action reversible in a few hours. Initially used upstream for treatment of patients with non ST-elevation acute coronary síndromes, recent evidence has shown its role as adjuntive therapy in pa...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - November 23, 2014 Category: Cardiology Tags: Cardiovasc Hematol Agents Med Chem Source Type: research
